At Aisthesis Medical, we believe the key to addressing AMR in sepsis care lies in prevention, precision, and timely intervention.
We are delighted to announce that Aisthesis Medical has been selected as part of the UK delegation for the Innovate UK Antimicrobial Resistance (AMR) Global Business Innovation Programme in Switzerland!
This prestigious initiative brings together cutting-edge innovators tackling the global AMR crisis, and we are thrilled to showcase how VIOSync—our AI-driven sepsis care platform—is redefining early detection and reducing unnecessary antibiotic use.
Why This Matters
Antimicrobial resistance is one of the greatest challenges facing modern healthcare, threatening to undermine decades of medical progress. Infections that were once easily treatable are becoming resistant to existing therapies, leading to higher mortality rates, longer hospital stays, and increased healthcare costs.
At Aisthesis Medical, we believe the key to addressing AMR in sepsis care lies in prevention, precision, and timely intervention.
How VIOSync is Changing the Game
- Early Detection: AI-powered sepsis predictions up to 48 hours before clinical symptoms appear
- Optimized Treatment: Reducing reliance on broad-spectrum antibiotics through precision-guided interventions
- Clinical Integration: Seamlessly embedding evidence-based sepsis bundles into hospital workflows to drive timely action
- Cost & Risk Reduction: Lowering sepsis-related complications, saving lives and healthcare resources
Expanding Global Collaborations
Through this programme, we are excited to engage with Swiss and European leaders in healthcare, AI, and AMR research. We look forward to fostering partnerships that will accelerate the adoption of innovative solutions for better patient outcomes worldwide.
If you are attending the AMR Conference in Basel this February, let’s connect! We’d love to discuss how AI-driven solutions like VIOSync can play a critical role in the fight against AMR.
About Aisthesis Medical
Aisthesis Medical is a deep-tech medtech startup developing cutting-edge AI-driven solutions to revolutionize acute care. Founded in 2022, our mission is to save lives by predicting and preventing sepsis before it becomes fatal. Aisthesis Medical is revolutionizing acute care with VIOSync, the first holistic AI-driven sepsis care platform that goes beyond early prediction to guide clinical intervention and optimize patient outcomes. VIOSync, predicts sepsis up to 48 hours earlier, integrates directly into hospital workflows, and optimizes treatment pathways to reduce unnecessary antibiotic use.